Cargando…
Risk and prognostic factors of breast cancer with liver metastases
BACKGROUND: Liver metastasis is a significant adverse predictor of overall survival (OS) among breast cancer patients. The purpose of this study was to determine the risk and prognostic factors of breast cancer with liver metastases (BCLM). METHODS: Data on 311,573 breast cancer patients from the Su...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937288/ https://www.ncbi.nlm.nih.gov/pubmed/33676449 http://dx.doi.org/10.1186/s12885-021-07968-5 |
_version_ | 1783661359649521664 |
---|---|
author | Ji, Lei Cheng, Lei Zhu, Xiuzhi Gao, Yu Fan, Lei Wang, Zhonghua |
author_facet | Ji, Lei Cheng, Lei Zhu, Xiuzhi Gao, Yu Fan, Lei Wang, Zhonghua |
author_sort | Ji, Lei |
collection | PubMed |
description | BACKGROUND: Liver metastasis is a significant adverse predictor of overall survival (OS) among breast cancer patients. The purpose of this study was to determine the risk and prognostic factors of breast cancer with liver metastases (BCLM). METHODS: Data on 311,573 breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database and 1728 BCLM patients from Fudan University Shanghai Cancer Center (FUSCC) were included. Logistic regression was used to identify risk factors for liver metastasis. Cox proportional hazards regression model was adopted to determine independent prognostic factors in BCLM patients. RESULTS: Young age, invasive ductal carcinoma, higher pathological grade, and subtype of triple-negative and human epidermal growth factor receptor 2 positive (HER2+) were risk factors for developing liver metastasis. The median OS after liver metastasis was 20.0 months in the SEER database and 27.3 months in the FUSCC dataset. Molecular subtypes also played a critical role in the survival of BCLM patients. We observed that hormone receptor-positive (HR+)/HER2+ patients had the longest median OS (38.0 for SEER vs. 34.0 months for FUSCC), whereas triple-negative breast cancer had the shortest OS (9.0 vs. 15.6 months) in both SEER and FUSCC. According to the results from the FUSCC, the subtype of HR+/HER2+ (hazard ratio (HR) = 2.62; 95% confidence interval (CI) = 1.88–3.66; P < 0.001) and HR−/HER2+ (HR = 3.43; 95% CI = 2.28–5.15; P < 0.001) were associated with a significantly increased death risk in comparison with HR+/HER2- patients if these patients did not receive HER2-targeted therapy. For those who underwent HER2-targeted therapy, however, HR+/HER2+ subtype reduced death risk compared with HR+/HER2- subtype (HR = 0.74; 95% CI = 0.58–0.95; P < 0.001). CONCLUSIONS: Breast cancer patients at a high risk for developing liver metastasis deserve more attention during the follow-up. BCLM patients with HR+/HER2+ subtype displayed the longest median survival than HR+/HER2- and triple-negative patients due to the introduction of HER2-targeted therapy and therefore it should be recommended for HER2+ BCLM patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-07968-5. |
format | Online Article Text |
id | pubmed-7937288 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79372882021-03-09 Risk and prognostic factors of breast cancer with liver metastases Ji, Lei Cheng, Lei Zhu, Xiuzhi Gao, Yu Fan, Lei Wang, Zhonghua BMC Cancer Research Article BACKGROUND: Liver metastasis is a significant adverse predictor of overall survival (OS) among breast cancer patients. The purpose of this study was to determine the risk and prognostic factors of breast cancer with liver metastases (BCLM). METHODS: Data on 311,573 breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) database and 1728 BCLM patients from Fudan University Shanghai Cancer Center (FUSCC) were included. Logistic regression was used to identify risk factors for liver metastasis. Cox proportional hazards regression model was adopted to determine independent prognostic factors in BCLM patients. RESULTS: Young age, invasive ductal carcinoma, higher pathological grade, and subtype of triple-negative and human epidermal growth factor receptor 2 positive (HER2+) were risk factors for developing liver metastasis. The median OS after liver metastasis was 20.0 months in the SEER database and 27.3 months in the FUSCC dataset. Molecular subtypes also played a critical role in the survival of BCLM patients. We observed that hormone receptor-positive (HR+)/HER2+ patients had the longest median OS (38.0 for SEER vs. 34.0 months for FUSCC), whereas triple-negative breast cancer had the shortest OS (9.0 vs. 15.6 months) in both SEER and FUSCC. According to the results from the FUSCC, the subtype of HR+/HER2+ (hazard ratio (HR) = 2.62; 95% confidence interval (CI) = 1.88–3.66; P < 0.001) and HR−/HER2+ (HR = 3.43; 95% CI = 2.28–5.15; P < 0.001) were associated with a significantly increased death risk in comparison with HR+/HER2- patients if these patients did not receive HER2-targeted therapy. For those who underwent HER2-targeted therapy, however, HR+/HER2+ subtype reduced death risk compared with HR+/HER2- subtype (HR = 0.74; 95% CI = 0.58–0.95; P < 0.001). CONCLUSIONS: Breast cancer patients at a high risk for developing liver metastasis deserve more attention during the follow-up. BCLM patients with HR+/HER2+ subtype displayed the longest median survival than HR+/HER2- and triple-negative patients due to the introduction of HER2-targeted therapy and therefore it should be recommended for HER2+ BCLM patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-07968-5. BioMed Central 2021-03-06 /pmc/articles/PMC7937288/ /pubmed/33676449 http://dx.doi.org/10.1186/s12885-021-07968-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Ji, Lei Cheng, Lei Zhu, Xiuzhi Gao, Yu Fan, Lei Wang, Zhonghua Risk and prognostic factors of breast cancer with liver metastases |
title | Risk and prognostic factors of breast cancer with liver metastases |
title_full | Risk and prognostic factors of breast cancer with liver metastases |
title_fullStr | Risk and prognostic factors of breast cancer with liver metastases |
title_full_unstemmed | Risk and prognostic factors of breast cancer with liver metastases |
title_short | Risk and prognostic factors of breast cancer with liver metastases |
title_sort | risk and prognostic factors of breast cancer with liver metastases |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937288/ https://www.ncbi.nlm.nih.gov/pubmed/33676449 http://dx.doi.org/10.1186/s12885-021-07968-5 |
work_keys_str_mv | AT jilei riskandprognosticfactorsofbreastcancerwithlivermetastases AT chenglei riskandprognosticfactorsofbreastcancerwithlivermetastases AT zhuxiuzhi riskandprognosticfactorsofbreastcancerwithlivermetastases AT gaoyu riskandprognosticfactorsofbreastcancerwithlivermetastases AT fanlei riskandprognosticfactorsofbreastcancerwithlivermetastases AT wangzhonghua riskandprognosticfactorsofbreastcancerwithlivermetastases |